Clinical Trial Search

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Number of Participants With Objective Response — 9 participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Overall Objective Response Rate During Treatment Cycle 1 — 57.1; 100.0; 30.8 percentage of participants

Primary: Percentage of Patients With an Overall Response to Study Drug — 24.3; 12.5 percentage of participants

Primary: Clinical Response Rate — 2; 0; 1; 1 participants

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 24; 28; 9; 8 Participants

Primary: ORR — 13 Participants

Primary: The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma — 62.7 Percentage…

Primary: Event Free Survival (EFS) Per Blinded Central Assessment — 8.3; 2.0 months — p=<0.0001

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) — 6; 10; 11; 0 Participants

Primary: Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) of Mogamulizumab in Combination With Pembrolizumab (Phase I) — 0; 1; 2; 0 Participants

Primary: Objective Response Rate (ORR) in Total Population Based on Investigator Assessment — 19.4; 25.0 Percentage of participants

Primary: Participants With Adverse Events — 0; 15; 15 percentage of participants

Primary: Objective Response Rate — 3 Participants

Primary: Objective Tumor Response — 0 participants

Primary: Progression-free Survival as Assessed by Independent Reviewers — 2.14; 1.81 Months — p=0.333

Primary: Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization — 10 Participants

Primary: Objective Response Rate (ORR) — 47.5; 46.2; 43.6 Percentage of participants — p=0.5543

Primary: Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 6; 7 Participants

Primary: Objective Response Rate (ORR) Per Independent Radiologic Review Committee (IRRC) Assessment — 10.3; 2.9 Percent of participants

Primary: Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL. — 3; 2 Participants

Primary: Progression-free Survival — 72 Percent

Primary: Overall Response Rate (ORR) — 48.3 percentage of participants